Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 27, 2021

Boehringer to start Phase III study of alteplase to treat Covid-19

The company will start the Phase III TRISTARDS clinical trial of alteplase in the context of its Covid-19 therapy research.

Boehringer Ingelheim has plans to commence the Phase III part of its Phase II/III TRISTARDS clinical trial of alteplase to treat Covid-19 patients suffering from acute respiratory distress syndrome (ARDS).

The announcement comes after the drug showed favourable safety and efficacy profile in an interim analysis of the trial, in which the exploratory open-label Phase IIb part with 62 participants is complete.

During the Phase IIb part, the efficacy and safety of two intravenous alteplase dosing regimens administered over up to five days along with the standard of care (SOC) were compared to SOC alone.

Based on the Phase II data, the company decided to direct its Covid-19 therapy research on developing an alteplase.

The plan is to begin the Phase III part of TRISTARDS in the fourth quarter of this year to validate and additionally evaluate the drug’s effects in Covid-19-related ARDS patients.

Boehringer also intends to start preparations for potential applications to seek regulatory approval.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Boehringer Ingelheim board of managing directors member Michel Pairet said: “If the Phase III part of TRISTARDS confirms the favourable interim results from the Phase II, alteplase could have the potential to become a new therapy option for the most severely affected Covid-19 patients.”

Alteplase is said to be the first licensed treatment to dissolve blood clots for acute ischemic stroke treatment.

The drug can also be used to treat acute myocardial infarction, acute massive pulmonary embolism and catheter clearance associated with thrombotic occlusion.

Boehringer launched the TRISTARDS trial after investigator-initiated studies indicated the drug’s potential for treating Covid-19 ARDS in patients who are severely ill.

Apart from focusing on alteplase for Covid-19, the company has decided to discontinue the development programme of BI 767551 SARS-CoV-2 neutralising antibody.

The decision is based on evolving SARS-CoV-2 landscape, including the success of vaccines, existing neutralising antibody programmes and emerging variants.

The programme of Boehringer’s neutralising antibody included trials analysing the delivery through inhalation, which the company expects to be a feasible route of administration for quick activity onset.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy